Missed Dose Protocol for GLP-1 Medications: What to Do
Learn exactly what to do if you miss a dose of semaglutide, tirzepatide, or liraglutide — with evidence-based guidelines and pharmacokinetic data.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 15, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Missing a dose of a GLP-1 receptor agonist is more common than many patients expect — real-world data show that adherence challenges affect a significant portion of users. Yet the consequences of a missed injection depend heavily on the specific medication's half-life, how long ago the dose was due, and what you do next.
Evidence: A large US cohort study found that approximately 64% of patients on GLP-1 medications for obesity discontinued within one year, with GI side effects and logistical barriers (including missed doses) as primary drivers. — Rodriguez PJ, et al. JAMA Network Open. 2025. DOI: 10.1001/jamanetworkopen.2024.57349
This guide covers the evidence-based missed dose protocol for the three most prescribed GLP-1 medications: semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide (Saxenda/Victoza).
Why Half-Life Is the Key to Missed Dose Decisions
GLP-1 receptor agonists work differently from medications you take daily. Their long biological half-lives are a deliberate design feature — and they are precisely what determines whether a missed dose matters clinically.
Semaglutide: ~7-Day Half-Life
Semaglutide's plasma half-life of approximately one week is the reason it can be dosed once weekly. Even if you miss an injection, meaningful plasma concentrations remain for several days.
Evidence: "Single subcutaneous doses of semaglutide 0.5 mg and 1 mg showed a half-life of approximately 1 week across healthy subjects and subjects with type 2 diabetes." — Granhall C, et al. Clinical Pharmacokinetics. 2019. DOI: 10.1007/s40262-018-0728-4
A 2024 systematic review of semaglutide's clinical pharmacokinetics further confirmed that the ~7-day half-life is consistent across all approved dose levels (0.25 mg through 2.4 mg), with peak plasma concentrations reached 1–3 days post-injection.
Evidence: "The pharmacokinetic profile of semaglutide — including its prolonged half-life of ~7 days — supports once-weekly subcutaneous dosing and provides a buffer against single missed doses." — Yang XD, Yang YY. Drug Design, Development and Therapy. 2024. DOI: 10.2147/DDDT.S470826
Tirzepatide: ~5-Day Half-Life
Tirzepatide (a dual GIP/GLP-1 receptor agonist) has a somewhat shorter half-life of approximately 5 days, which still supports once-weekly dosing but with a slightly narrower window for missed dose recovery.
Evidence: A Phase 1 multiple-ascending dose study in Japanese participants with type 2 diabetes measured tirzepatide's terminal half-life at approximately 5 days across all dose groups. — Furihata K, et al. Diabetes, Obesity and Metabolism. 2022. DOI: 10.1111/dom.14572
A population pharmacokinetic analysis pooling 19 tirzepatide clinical trials confirmed these findings and characterized tirzepatide's disposition with a two-compartment model — the same PK model used to derive missed-dose instructions in the prescribing label.
Evidence: "Population PK analysis across 19 studies described tirzepatide's pharmacokinetics with a two-compartment model. The half-life supports once-weekly dosing with predictable concentration-time profiles." — Schneck K, Urva S. CPT Pharmacometrics Syst Pharmacol. 2024. DOI: 10.1002/psp4.13099
Missed Dose Protocol by Medication
Semaglutide (Ozempic / Wegovy)
Official prescribing guidance:
| Time Since Missed Dose | Action |
|---|---|
| Within 5 days of scheduled injection | Take the missed dose as soon as you remember |
| More than 5 days have passed | Skip the missed dose entirely |
| Both cases | Resume your regular weekly schedule from the original day |
Key rules:
- Never double-dose to compensate
- The next injection should remain on your usual day of the week
- If you miss multiple consecutive doses, contact your healthcare provider before restarting — nausea and GI side effects may return as your body readjusts
Tirzepatide (Mounjaro / Zepbound)
Official prescribing guidance:
| Time Since Missed Dose | Action |
|---|---|
| Within 4 days of scheduled injection | Take the missed dose as soon as you remember |
| More than 4 days have passed | Skip the missed dose entirely |
| Both cases | Resume your regular weekly schedule |
The 4-day cutoff (vs. semaglutide's 5-day cutoff) reflects tirzepatide's slightly shorter half-life.
Liraglutide (Saxenda / Victoza)
Liraglutide is a daily injection with a much shorter half-life of approximately 13 hours.
| Time Since Missed Dose | Action |
|---|---|
| Same day (any time) | Take the missed dose |
| Next day or later | Skip and resume normal daily schedule |
Because of liraglutide's short half-life, missing even a single day results in substantially reduced plasma drug concentrations — more so than with weekly agents.
What Happens Clinically When You Miss a Dose
Short-Term Effects (1–2 Missed Doses)
For weekly GLP-1s (semaglutide, tirzepatide), missing one or two doses within the 4–5 day window and then reinjecting typically produces minimal clinical disruption. The long half-life provides a pharmacokinetic buffer. You may notice slightly increased appetite or less satiety in the days before your next dose.
Restarting After Extended Breaks
If you've missed two or more consecutive weekly doses — or stopped treatment for any reason — the situation changes meaningfully. Plasma concentrations will have dropped significantly, and the medication will effectively need to restart from a lower concentration baseline.
Clinically important consequences include:
- GI side effects may return: nausea, vomiting, and diarrhea often re-emerge when restarting, similar to initial titration
- Weight rebound: data consistently show weight regain after GLP-1 discontinuation, often beginning within weeks
Evidence: Mathematical modelling of extended and missed dosing intervals found that biweekly dosing maintained meaningful weight loss efficacy due to the long pharmacokinetic tail of semaglutide — suggesting that even an occasional missed weekly dose has limited long-term impact when adherence is otherwise good. — Cengiz A, et al. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16229
Practical guidance after extended breaks:
- Consult your prescriber before restarting
- Many clinicians recommend restarting at a lower dose (e.g., returning to 0.25 mg semaglutide) to allow GI re-adaptation
- Do not restart at the dose you left off if you've been off for more than 2 weeks
Common Scenarios and What to Do
"I forgot which day I inject — it's been about a week"
Calculate as best you can. If it's been approximately 7 days, go ahead and take your regular dose on your newly established day. You haven't technically missed anything clinically meaningful.
"I was sick and couldn't inject for 10 days"
Skip the past doses entirely. Do not catch up. Contact your provider — you may need to restart at a lower titration dose to manage side effects.
"I ran out of medication and my refill took 2 weeks"
This is a medication gap, not a single missed dose. Expect GI side effects when restarting. Inform your provider. Depending on your dose level, down-titration may be appropriate.
"I accidentally injected twice in one week"
Do not repeat the next scheduled dose early. Monitor for side effects (nausea, vomiting, hypoglycemia if on concomitant insulin or sulfonylureas). Contact your provider if you have significant symptoms. Return to your regular schedule the following week.
Tips for Preventing Missed Doses
- Set a recurring weekly phone alarm — label it with the medication name and dose
- Link injection day to a fixed weekly event (Monday morning routine, etc.)
- Use the medication manufacturer app — Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) both offer reminder tools
- Keep your medication visible — stored properly per GLP-1 storage guidelines, but in a place you won't forget
- Travel preparation — review the GLP-1 travel protocol before trips, as disrupted routines are a leading cause of missed doses
Key Takeaways
- Semaglutide: inject within 5 days of missed dose — otherwise skip and resume normal schedule
- Tirzepatide: inject within 4 days — otherwise skip
- Liraglutide (daily): take same day — otherwise skip entirely
- Never double-dose
- After extended breaks (2+ weeks), consult your provider before restarting — down-titration is often warranted
- A single missed weekly dose has limited clinical impact due to the long pharmacokinetic half-lives of these medications
References
Rodriguez PJ, Zhang V, Gratzl S, et al. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open. 2025;8(1):e2457349. DOI: 10.1001/jamanetworkopen.2024.57349
Granhall C, Donsmark M, Blicher TM, et al. Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Oral Semaglutide in Healthy Subjects and Subjects with Type 2 Diabetes. Clinical Pharmacokinetics. 2019;58(6):781–791. DOI: 10.1007/s40262-018-0728-4
Yang XD, Yang YY. Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug Design, Development and Therapy. 2024;18:2555–2570. DOI: 10.2147/DDDT.S470826
Furihata K, Mimura H, Urva S, et al. A Phase 1 Multiple-Ascending Dose Study of Tirzepatide in Japanese Participants with Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2022;24(2):239–246. DOI: 10.1111/dom.14572
Schneck K, Urva S. Population Pharmacokinetics of the GIP/GLP Receptor Agonist Tirzepatide. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(3):494–503. DOI: 10.1002/psp4.13099
Cengiz A, Wu CC, Lawley SD. Alternative Dosing Regimens of GLP-1 Receptor Agonists May Reduce Costs and Maintain Weight Loss Efficacy. Diabetes, Obesity and Metabolism. 2025;27(4):2251–2258. DOI: 10.1111/dom.16229
Last updated: 2026-03-15 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.